TableĀ 3

Detection of KRAS exon 2 mutations in 51 FFPE CRC samples by three methods

Patient NoExonTumour cell percentage (%)Ion torrent PGMScorpions-ARMS VariantsSanger Variants
VariantsCoverage (X)Frequency (%)
2265p.G13D(c.38G>A)54638.5p.G13D(c.38G>A)p.G13D(c.38G>A)
3285p.G12D(c.35G>A)211049.8p.G12D(c.35G>A)p.G12D(c.35G>A)
6290p.G12D(c.35G>A)64028.1p.G12D(c.35G>A)p.G12D(c.35G>A)
15270p.G12D(c.35G>A)60923.0p.G12D(c.35G>A)p.G12D(c.35G>A)
18280p.G12D(c.35G>A)36950.1p.G12D(c.35G>A)p.G12D(c.35G>A)
20285p.G12V(c.35G>T)82056.6p.G12V(c.35G>T)p.G12V(c.35G>T)
24270p.G12D(c.35G>A)103554.2p.G12D(c.35G>A)p.G12D(c.35G>A)
25270p.G12D(c.35G>A)156053.4p.G12D(c.35G>A)p.G12D(c.35G>A)
34280p.G12D(c.35G>A)88527.9p.G12D(c.35G>A)p.G12D(c.35G>A)
35265p.G13D(c.38G>A)63936.3p.G13D(c.38G>A)p.G13D(c.38G>A)
37290p.G13C(c.37G>T)62859.1NDp.G13C(c.37G>T)
42275p.G12D(c.35G>A)158022.2p.G12D(c.35G>A)p.G12D(c.35G>A)
44280p.G12D(c.35G>A)172831.7p.G12D(c.35G>A)p.G12D(c.35G>A)
  • Bold typeface indicates the discrepant case among three methods.

  • CRC, colorectal cancer; FFPE, formalin-fixed paraffin-embedded; ND, mutation status could not be determined by the Therascreen kit.